Cloudbreak Pharma, Inc

Cloudbreak Pharma, Inc.(2592.HK) is an innovative, clinical-stage biotechnology company with a robust R&D engine for development of first and best-in-class ophthalmic drugs. Founded in the United States in 2015 with a headquarters in Irvine, California, the company also has administrative, R&D and manufacturing branches in mainland China and Hong Kong. The Company’s leading technology includes multi-kinase inhibitors, with Phase 3 assets for the treatment of pterygium and pinguecula. There are currently no approved drug therapies for these conditions that impact over a billion people globally. The Company’s second technology is a semi-fluorinated alkane (SFA+) non-aqueous delivery system that is included in CBT-199 and other drug candidates. With its innovative pipeline of eight drug candidates for both the front and back-of-the-eye, the company strives towards “Seeing Life Better, Through Medicine.”